445 related articles for article (PubMed ID: 12069500)
1. Vascular endothelial growth factor-mediated angiogenesis inhibition and postoperative wound healing in rats.
Roman CD; Choy H; Nanney L; Riordan C; Parman K; Johnson D; Beauchamp RD
J Surg Res; 2002 Jun; 105(1):43-7. PubMed ID: 12069500
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis.
Haspel HC; Scicli GM; McMahon G; Scicli AG
Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy.
Wood JM
Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of inducible nitric oxide synthase results in reductions in wound vascular endothelial growth factor expression, granulation tissue formation, and local perfusion.
Howdieshell TR; Webb WL; Sathyanarayana ; McNeil PL
Surgery; 2003 May; 133(5):528-37. PubMed ID: 12773981
[TBL] [Abstract][Full Text] [Related]
5. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models.
Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C
Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925
[TBL] [Abstract][Full Text] [Related]
6. The angiogenesis inhibitor SU5416 has long-lasting effects on vascular endothelial growth factor receptor phosphorylation and function.
Mendel DB; Schreck RE; West DC; Li G; Strawn LM; Tanciongco SS; Vasile S; Shawver LK; Cherrington JM
Clin Cancer Res; 2000 Dec; 6(12):4848-58. PubMed ID: 11156244
[TBL] [Abstract][Full Text] [Related]
7. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types.
Fong TA; Shawver LK; Sun L; Tang C; App H; Powell TJ; Kim YH; Schreck R; Wang X; Risau W; Ullrich A; Hirth KP; McMahon G
Cancer Res; 1999 Jan; 59(1):99-106. PubMed ID: 9892193
[TBL] [Abstract][Full Text] [Related]
8. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro.
Abdollahi A; Lipson KE; Han X; Krempien R; Trinh T; Weber KJ; Hahnfeldt P; Hlatky L; Debus J; Howlett AR; Huber PE
Cancer Res; 2003 Jul; 63(13):3755-63. PubMed ID: 12839971
[TBL] [Abstract][Full Text] [Related]
9. The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression.
Litz J; Sakuntala Warshamana-Greene G; Sulanke G; Lipson KE; Krystal GW
Lung Cancer; 2004 Dec; 46(3):283-91. PubMed ID: 15541812
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy.
Geng L; Donnelly E; McMahon G; Lin PC; Sierra-Rivera E; Oshinka H; Hallahan DE
Cancer Res; 2001 Mar; 61(6):2413-9. PubMed ID: 11289107
[TBL] [Abstract][Full Text] [Related]
11. The angiogenic peptide vascular endothelial growth factor (VEGF) is expressed during the remodeling of free tendon grafts in sheep.
Petersen W; Unterhauser F; Pufe T; Zantop T; Südkamp NP; Weiler A
Arch Orthop Trauma Surg; 2003 May; 123(4):168-74. PubMed ID: 12734715
[TBL] [Abstract][Full Text] [Related]
12. VEGFR-2 antagonist SU5416 attenuates bleomycin-induced pulmonary fibrosis in mice.
Ou XM; Li WC; Liu DS; Li YP; Wen FQ; Feng YL; Zhang SF; Huang XY; Wang T; Wang K; Wang X; Chen L
Int Immunopharmacol; 2009 Jan; 9(1):70-9. PubMed ID: 18976720
[TBL] [Abstract][Full Text] [Related]
13. Flk-1 specific kinase inhibitor (SU5416) inhibited the growth of GS-9L glioma in rat brain and prolonged the survival.
Takamoto T; Sasaki M; Kuno T; Tamaki N
Kobe J Med Sci; 2001 Aug; 47(4):181-91. PubMed ID: 11733657
[TBL] [Abstract][Full Text] [Related]
14. Antibody neutralization of vascular endothelial growth factor inhibits wound granulation tissue formation.
Howdieshell TR; Callaway D; Webb WL; Gaines MD; Procter CD; Sathyanarayana ; Pollock JS; Brock TL; McNeil PL
J Surg Res; 2001 Apr; 96(2):173-82. PubMed ID: 11266270
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas.
Angelov L; Salhia B; Roncari L; McMahon G; Guha A
Cancer Res; 1999 Nov; 59(21):5536-41. PubMed ID: 10554031
[TBL] [Abstract][Full Text] [Related]
16. Wound-induced angiogenesis and its pharmacologic inhibition in a murine model.
Gelaw B; Levin S
Surgery; 2001 Sep; 130(3):497-501. PubMed ID: 11562675
[TBL] [Abstract][Full Text] [Related]
17. Blockade of in vivo VEGF-KDR/flk-1 signaling does not affect revascularization of freely transplanted pancreatic islets.
Schramm R; Yamauchi J; Vollmar B; Vajkoczy P; Menger MD
Transplantation; 2003 Jan; 75(2):239-42. PubMed ID: 12548132
[TBL] [Abstract][Full Text] [Related]
18. Relationship between vascular endothelial growth factor and angiogenesis in spontaneous and indomethacin-delayed healing of acetic acid-induced gastric ulcers in rats.
Suzuki N; Takahashi S; Okabe S
J Physiol Pharmacol; 1998 Dec; 49(4):515-27. PubMed ID: 10069693
[TBL] [Abstract][Full Text] [Related]
19. Recombinant leptin administration improves early angiogenesis in full-thickness skin flaps: an experimental study.
Liapakis IE; Anagnostoulis S; Karayiannakis AJ; Korkolis DP; Lambropoulou M; Arnaud E; Simopoulos CE
In Vivo; 2008; 22(2):247-52. PubMed ID: 18468410
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases.
Giles FJ; Cooper MA; Silverman L; Karp JE; Lancet JE; Zangari M; Shami PJ; Khan KD; Hannah AL; Cherrington JM; Thomas DA; Garcia-Manero G; Albitar M; Kantarjian HM; Stopeck AT
Cancer; 2003 Apr; 97(8):1920-8. PubMed ID: 12673719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
